+ and CD8 + T cells isolated from the spleen of vaccinated animals, however, in vivo depletion experiments showed that IL12 vaccine effect was CD4
Introduction
Despite intensive chemotherapy regimens, adult patients with acute leukemia achieve long-term survival in only 20 to 30% of cases. The example of graft-versus-leukemia effect observed in allogeneic bone marrow transplantation suggests that an efficient immune response can cure acute leukemia. A whole cell vaccine approach by ex vivo gene transfer in acute leukemia would have many advantages: leukemic cells are easy to collect, maintain in short-term culture, and freeze. In addition, most patients with acute leukemia achieve complete remission after conventional chemotherapy with a state of minimal residual disease that could be eradicated by the immune response induced by a gene therapy protocol. Several groups have reported the induction of an efficient and longlasting autologous immunity in murine leukemic models using gene transfer of CD80 and CD86 costimulatory molecules, GM-CSF, IL2, cytokines and CD154. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] IL12 gene transfer has been reported to induce the regression of a considerable preestablished leukemic burden in mice. 13 IL12 is a heterodimeric glycoprotein composed of a 35 and 40 kDa subunit. IL12 activates natural killer (NK) cells and cytotoxic T lymphocytes (CTL) and induces generation of T helper type 1 (Th1) cells. 14 IL12 gene transfer alone or combined with IL2 or B7.1 has demonstrated a strong antitumor activity in solid tumor models, which seemed to be induced at least in part by interferon-␥ (IFN␥) secretion. 15, 16 One of the main sources of IL12 is antigen-presenting cells (APC) such as dendritic cells. It has been previously shown that CD4 T cells expressing CD154 (CD40 ligand) may activate dendritic cells through the CD40 receptor leading to the production of several cytokines including IL12. 17 CD154 is a member of the tumor necrosis factor (TNF) gene family and is essential for the initiation of antigenspecific response. 18 CD154 gene transfer induces an antitumor immunity in various solid tumor models, in few models of acute leukemia, and more recently in a clinical trial in human chronic lymphocytic leukemia. 19 It has been shown that the antitumor effect of CD154 is mediated by induction of CTL but also that activated dendritic cells directly trigger NK cell antitumor functions. 20 Taken together these studies suggest that CD154 and IL12 share several pathways to induce immune antitumor response. The aim of our study was to compare the efficacy of CD154, IL12 and CD154 + IL12 gene transfer-mediated antileukemic immunity in our aggressive murine model of acute leukemia, and to investigate how T and NK cells were affected by gene transfer.
Materials and methods

Mouse model
Female C3H/HeJ 8-to 10-week-old mice were obtained from IFFA CREDO (Lyon, France). Establishment of leukemic DA1-3b cell line has been described previously. [21] [22] [23] Briefly, DA1 IL3-dependent cells were electroporated with a pCDNA3 expression vector (InVitrogen, San Diego, CA, USA) carrying a p210 BCR/ABL cDNA, and transduced cells were selected by culture in IL3-free medium. The DA1-3b cell line was maintained in liquid culture in DMEM medium (Life Technologies, Gaithersburg, MD, USA) supplemented with 10% fetal calf serum (FCS), 100 IU penicillin, 100 g/ml streptomycin, 2 mmol/l L-glutamine. Mice injected i.p. with 10 4 to 10 6 DA1-3b cells developed systemic lethal leukemia in 3 to 4 weeks with massive infiltration of bone marrow, spleen, and peripheral blood. 22 Expression of the two subunits of the IL12 receptor in the DA1-3b cell line was determined by RT-PCR using the following sets of primer: IL12 receptor ␤1 (IL12R␤1): 5Ј-GAACCACACACACTGTACCCTG-3Ј, 5Ј-TTTAGTGGGTGGC ACGAGCC-3Ј; IL12 receptor ␤2 (IL12R␤2): 5Ј-CAAGA CATCGACTATGACAGAC-3Ј, 5Ј-CAGGTTGTGCTGTCGAGT CTCG-3Ј. Expression of CD40 in DA1-3b cells was determined by flow cytometry using an anti-mouse CD40-FITC antibody (Pharmingen, San Diego, CA, USA).
Transfection of DA1-3b cells
IL12 and CD154 murine cDNA (kindly provided by Kris Thielemans, VUB, Brussels, Belgium) were inserted into the pCDNA3.1/Zeo expression plasmid (InVitrogen). DA1-3b
Leukemia cells were electroporated at 1500 F and 250 V and further selected with Zeomicin (InVitrogen). Transgene expression of CD154 was analyzed by flow cytometry after incubation with a murine anti-CD16/CD32 (Fc Block), using a phycoerythrinconjugated anti-CD154 (clone MR1) Armenian hamster IgG monoclonal antibody (Pharmingen) and isotype control. IL12 expression was assessed by ELISA IL-12 kit OptEIA mouse IL-12 (p70) (Pharmingen). Large batches of selected transduced bulks were frozen until use.
In vivo immunization studies
Groups of C3H/HeJ mice were injected i.p. or intravenously with live or irradiated (10 000 cGy from a 137 C source) CD154, IL12, and a mix of equal numbers of CD154 and IL12 transduced DA1-3b cells. DA1-3b cells transfected with the pCDNA3.1/Zeo empty plasmid, or wild-type DA1-3b cells were injected as control. Cells were diluted in 200 l of phosphate buffer saline (PBS) before injection. 
In vivo depletion studies
NK assay
A total of 15 mice per group in three separate experiments of five mice per group were injected subcutaneously with 10 6 irradiated CD154, IL12, a mix of equal number of CD154 and IL12 transduced cells, and control cells transfected with the empty pCDNA3.1/Zeo plasmid and wild-type DA1-3b cells. Injections were repeated four times (one every 3 days) 1 week after the last injection of irradiated transduced cells. All mice were injected with 10 5 wild-type non-irradiated DA1-3b cells. Another week later mice were killed and the spleen was removed. NK cells were isolated using the Miltenyi-Biotec separation column with an anti-DX5 monoclonal antibody, according to the manufacturer's recommendations (MiltenyiBiotec, Bergisch Gladbach, Germany). Purity of NK cell samples was analyzed by flow cytometry using B220 and anti-CD122 monoclonal antibody (Pharmingen). NK cell cytotoxicity was analyzed the same day using the CytoTox 96 nonradioactive cytotoxicity assay (Promega, Madison, WI, USA) by mixing NK cells isolated from the spleen as effectors and DA1-3b or K562 cells as targets, at various ratios.
CTL assay
Lymphocytes were isolated from harvested spleen of 15 mice per group in three separate experiments injected subcutaneously with 10 6 irradiated IL12 transduced cells or control DA1-3b-pCDNA3.1/Zeo or naive mice, with the MiltenyiBiotec separation column with an anti-CD90 (Thy1.2) monoclonal antibody. CD90
+ cells were co-cultured with irradiated DA1-3b cells and 20 IU murine IL2/ml (Peprotech, Rocky Hill, USA) in 3 ml/well of a six-well tissue culture plate. CTL activity was measured after 0, 7 and 15 days of co-culture, using the CytoTox 96 non-radioactive cytotoxicity assay (Promega) with cultured cells isolated as effectors, and DA1-3b cells as targets at various ratios. Controls also included cells isolated from DA1-3b-IL12 vaccinated mice as effectors and human K562 cells and EL4-BCR/ABL transfected cell line as targets. Immunophenotype of effector cells was determined by flow cytometry using the following MoAb antibody: CD8-FITC (rat anti-mouse IgG2a, kappa), CD3-PE (rat anti-mouse IgG2b, kappa), CD3-FITC (rat anti-mouse IgG2b, kappa), CD4-PE (rat anti-mouse IgG2a, kappa), Pan NK-FITC (rat antimouse IgM, kappa) (Pharmingen).
Quantification of IL4 and IFN␥ mRNA by RTcompetitive PCR
Spleens removed from mice immunized as described above in the NK cytotoxicity experiments were used for separation of CD4 and CD8 T cells using Miltenyi-Biotec separation columns and anti-CD4 and anti-CD8 monoclonal antibodies (Miltenyi-Biotec). After incubation of samples in RNAzol, total RNA (5-10 g) was reverse transcripted into cDNA. After treatment at 37°C for 30 min with 20-50 units of DNase I RNase-free (Boehringer, Mannheim, Germany), the quantity and purity of RNA were estimated by determining absorbance at 260/280 nm. Total RNA (5-10 g) was reverse transcripted into cDNA using Moloney Murine Leukemia virus reverse transcriptase (Gibco-BRL, Cergy Pontoise, France), 5 M oligo-dT16, and 2.5 mM of each of the 4 dNTP (Pharmacia, Orsay, France) in a final reaction volume of 20 l in the presence of 1 U/l of human placenta Ribonuclease Inhibitor (Promega, Lyon, France). Samples were incubated at 42°C for 60 min followed by heating for 5 min at 95°C to deactivate the enzyme and then stored at −20°C until use. The RT reaction mixture was amplified by PCR using sense and antisense primers specific for ␤-actin, IL4, and IFN␥ with various primer and competitor ratios. The samples were subjected to 40 PCR cycles, consisting of denaturation for 1 min at 94°C, primer annealing for 1 min at 52-58°C, and primer extension for 1.5 min at 72°C using a Gene Amp PCR System 9700 (PerkinElmer Corporation, Foster City, CA, USA). After PCR amplification, quantification of IL4 and IFN␥ cDNA was performed by electrophoresis in 2-3% agarose gel as previously described, using an image analyzer (Gel Analyst, Clara Vision, Paris, France). 24 The quantity of mRNA was expressed as the number of IL4 and IFN␥ cDNA molecules per ␤-actin cDNA molecules.
Statistical analysis
Statistical analysis was performed with the SPSS 10 software (SPSS, Chicago, IL, USA).
Results
Transgene expression
DA1-3b cells transduced with CD154 were 70% positive for CD154 expression in flow cytometry analysis. One hundred Gy irradiation did not affect CD154 expression. DA1-3b IL12 transduced cells produced 1500 ng of IL12 per 10 6 cells per 24 h. After irradiation these cells produced 2500-ng/10 6 cells/24 h. In order to investigate possible autocrine effects of the transgene, we analyzed the expression of the two subunits of the IL12 receptor and CD40 in DA1-3b cells. No CD40 expression could be detected and only the IL12R␤1 subunit mRNA of the IL12 receptor was expressed either in transduced or wild-type DA1-3b cells. Growth curves in vitro of IL12, CD154, pCDNA3/Zeo transduced, and wild-type DA1-3b cells did not show any significant differences.
Inhibition of leukemogenicity
Effect of gene transfer on leukemogenicity was investigated by i.p. injection of 10 5 and 10 6 transduced or control DA1-3b cells in a total of 30 C3H/HeJ mice in three separate experiments ( Figure 1 ). We observed that mice injected with 10 5 living IL12, CD154, and IL12 + CD154 transduced DA1-3b cells showed significantly reduced tumorigenicity (P Ͻ 10 −4 , P = 0.0078, P Ͻ 10 −4 , respectively log-rank test), and both IL12 and the combination of IL12 + CD154 transduced cells were superior to CD154 alone and differences increased when 10 6 cells were injected (Figure 1 ).
Vaccine and therapeutic effects
The vaccine effect of irradiated transduced DA1-3b cells was evaluated by four subcutaneous injections of 10 6 transduced
Figure 1
Tumorigenicity experiments: i.p. injection of 10 5 and 10 6 transduced DA1-3b cells in 30 C3H mice/group. Experiments were repeated three times. Probabilities of survival are plotted as Kaplan-Meier curves.
Leukemia DA1-3b cells irradiated at 100 Gy and delivered every 3 days (Figure 2 ). The dose of irradiation chosen was the minimum dose preventing further growth of DA1-3b cells in vivo. Antileukemic immunity was challenged 1 week after the last injection of vaccine cells by i.p. injection of 10 4 , 10 5 and 10 6 wildtype DA1-3b cells in 15 to 30 C3H mice/group in three separate experiments. Mice challenged with 10 4 DA1-3b cells were protected in IL12, CD154, and CD154 + IL12 groups. We observed a minor improvement of survival in mice challenged with 10 5 DA1-3b cells, but no protection was observed in mice challenged with 10 6 DA1-3b cells. Finally, we investigated the potential therapeutic effect of gene transfer by first injecting 10 4 wild-type DA1-3b cells in 30 C3H mice/group in three separate experiments followed by eight subsequent subcutaneous injections of irradiated transduced cells delivered twice a week. Injections of IL12 transduced cells led to a significant therapeutic effect (P = 0.0035, logrank test) (Figure 3) . 
NK cell cytotoxicity and cytokine production in T cells
As spleen is massively involved by leukemic cells in the DA1-3b/C3H model, we analyzed NK cell cytotoxicity against Therapeutic experiments: prior intraperitoneous injection of 10 4 wild-type DA1-3b cells followed 3 days later by eight subsequent subcutaneous injections of 10 6 irradiated transduced cells delivered twice a week. Thirty C3H mice/group were injected and experiments were repeated three times. Probabilities of survival are plotted as Kaplan-Meier curves.
Figure 4
Adoptive transfer of antileukemic immunity by transplantation of splenocytes in 15 C3H mice/group. Experiments were repeated two times. Control group includes mice injected IP with splenocytes isolated from non-immunized mice.
DA1-3b and K562 cells in NK cells isolated from the spleen of vaccinated animals and challenged with wild-type DA1-3b cells. 22 The cytotoxicity assay showed significantly higher NK cell-mediated lysis of DA1-3b and K562 cells in groups of mice vaccinated with IL12, CD154, and CD154 + IL12 transduced cells ( Figure 5 ). The highest percentage of lysis was obtained in the CD154 + IL12 group (P = 0.03, Student's ttest).
Quantification of IL4 and IFN␥ mRNA by RT-competitive PCR in CD4 + and CD8 + T lymphocytes from the spleen of vaccinated animals showed that IL12 transduced cells induced significantly higher production of IFN␥ mRNA in CD4 + and CD8 + T cells (P = 0.028 and P = 0.01, respectively, Student's t-test) ( Figure 6 ). CD154 and CD154 + IL12 transduced cells induced lower production of IFN␥ ( P = 0.01, P = 0.03, respectively) in CD4 T cells. In CD8 T cells, IFN␥ mRNA production was lower in the CD154 group and higher in the IL12 and CD154 + IL12 groups (P = 0.024, P = 0.03, P = 0.028, respectively). IL4 mRNA production showed no modification in any group.
CTL assay and in vivo depletion studies
We also investigated if, in addition to enhanced NK cell cytotoxicity, IL12 transduced cells induced CTL activity against DA1-3b cells. We isolated lymphocytes from the spleen of vaccinated animals using anti-CD90
+ cell microbeads and cocultured these cells with irradiated DA1-3b cells. After 1 week of culture, cytotoxic activity of lymphocytes isolated from DA1-3b-IL12 vaccinated mice was detected against DA1-3b cells but also against human K562 cells and the murine EL4-BCR/ABL cell line. Immunophenotype at this time showed an increase proportion of NK cells. Specific cytotoxic activity against DA1-3b cells was detected after 2 weeks of stimulation ( Figure 7) . Immunophenotype showed that co-cultured effector cells of the DA1-3b-IL12 group were 61% CD8 + T cells (Table 1) . We detected by RT-PCR in these effector cells IFN␥ but not IL4 mRNA. We did not detect IFN␥ mRNA in lymphocytes isolated from naive and DA1-3b-pCDNA3/Zeo vaccinated mice and cultured with or without irradiated DA1-3b cells.
Leukemia
Figure 6
Production of IFN␥ and IL4 mRNA by CD4-and CD8-positive T lymphocytes isolated from spleen of mice vaccinated with irradiated transduced DA1-3b cells. Data represent mean and s.e.m.of three separate experiments, each performed with three mice/group. As IL12 transduced cell vaccine led to the best protective effect and the highest production of IFN␥ mRNA in CD4 + and CD8 + T cells, we performed in vivo selective CD4 + and CD8 + T cell depletion in mice vaccinated with IL12 transduced or control PCDNA3/Zeo DA1-3b cells. Survival of mice vaccinated with IL12 transduced cells was impaired by depletion of CD4 + T cells (P = 0.018), but survival of CD8 + T cell-depleted animals was not affected (Figure 8 ).
Discussion
We observed in this report that injection of live leukemic cells transduced with CD154 or IL12 cDNA led to protection of mice. However, only mice injected with IL12 transduced cells were protected against a high number of cells. Survival results were not statistically different between mice receiving IL12 and CD154 + IL12 transduced cells, suggesting that most of the protective effect was mediated by IL12. Autocrine effects of the transgenes in DA1-3b cells seems unlikely to account for differences observed in vivo as DA1-3b cells did not express CD40, the CD154 receptor. DA1-3b cells also only expressed the IL12R␤1 but not the IL12R␤2 subunit of the IL12 receptor, and it has been shown previously that the IL12R␤2 subunit plays an essential role in mediating the biological functions of IL12 in mice. 25 Moreover, in vitro growth curves of IL12, CD154, and control pCNDA3/Zeo transduced and wild type DA1-3b cells were similar. Irradiated cells were Cytotoxic assay of lymphocytes harvested from spleen of mice vaccinated with DA1-3b-IL12, DA1-3b-pCDNA3/Zeo cells, or naive mice after 0, 7 and 15 days of stimulation by co-culture with irradiated DA1-3b cells. Data represent mean of three separate experiments, each performed with 15 mice/group. less efficient than non-irradiated cells, and required repeated injections in a short period of time to significantly inhibit the development of leukemia after injection of 10 4 wild-type leukemic cells. These findings are in contrast with those obtained by Dunussi-Joannopoulos et al, 13 who reported protection by IL12 transduced cell vaccine of 100% mice injected with 10 5 leukemic cells. Transgene expression seems unlikely to account for this discrepancy because IL12 production was higher after irradiation in our model, but we cannot rule out that a large amount of IL12 may induce adverse effects. According to this hypothesis, we found a slight increase of CD4 + and CD8 + T cells, and a more pronounced increase of NK cells in the spleen of mice vaccinated with irradiated IL12 transduced DA1-3b cells. Other groups have reported very conflicting data about the effect of irradiation of tumor cells on the immune response in animal models. For instance, Dunussi-Joannopoulos et al 6 reported efficient antileukemic response after gene transfer of B7.1 in murine leukemic cells, which was not affected by high-dose irradiation. They also did not find significant modification of spleen histology and proportion of lymphocyte subsets in mice vaccinated with irradiated IL12 transduced leukemic cells. In most animal models, irradiation of tumor cells enhanced immunogenicity even in untransfected cells. However, many groups have reported that vaccine and therapeutic experiments by gene transfer are less efficient than inhibition of tumorigenicity and it seems likely that this difference is related to the specific need of strong systemic immunity in vaccine and therapeutic experiments. Thus, differences of aggressiveness between mouse models seem more likely to explain some of the variation reported.
We also analyzed how leukemic cell vaccines affected the immune system of C3H/HeJ mice. We observed in mice vaccinated with subcutaneous injections of irradiated IL12, CD154 and CD154 + IL12 transduced DA1-3b cells an increase of NK cell cytotoxicity, and combined vaccine with CD154 and IL12 expressing cells induced significantly higher activity than CD154 or IL12 alone. IL12 is a known activator of NK cells and CD154 also activates NK cells via IL12 produced by APC stimulated by CD40, and also by direct interaction between APC and NK cells. 20 However, absence of correlation with survival of mice suggests that NK cell activity did not mediate the antileukemic effect observed in our model. We also observed, in agreement with previous published reports, that IFN␥ mRNA production was higher in CD4 T cells isolated from spleen of mice vaccinated with IL12 expressing leukemic cells suggesting a Th1 cytokine profile, and lower after injection of CD154 expressing vaccine. 26 We found CTL activity against DA1-3b cells in mice vaccinated with IL12 transduced cells, but only after repeated in vitro stimulation. In vivo depletion of T cell subsets in vaccinated animals showed that antileukemic immunity induced against DA1-3b cells was CD4 + but not CD8 + cell dependent, suggesting that CD8 + CTL did not mediate in vivo antileukemic immunity. However, Dunussi-Joannopoulos et al 13 reported that IL12 expressing cell vaccine induced in their model a strong CTL activity against leukemic cells but found no evidence of NK cell cytotoxicity, and the antileukemic response observed was CD8 + T cell, IL12, and IFN␥ dependent but also CD4 + independent. Thus it appears that mechanisms of IL12-induced antileukemic immunity are model dependent. Combined with our data, IFN␥ appears as a key cytokine for induction of antileukemic immunity.
The DA1-3b/C3H/HeJ murine leukemic model is highly aggressive, and DA1-3b cells are poorly differentiated leukemic cells that express few molecules of the immune system on their surface. 22 It appears that efficient systemic immunity against leukemic cells is difficult to induce in this model. Moreover, the DA1-3b/C3H/HeJ murine leukemic model has some characteristics of poorly differentiated human acute leukemia, which generally carries a poor prognosis. Thus, a longterm survival of 27% in therapeutic experiments appears as a significant result of immunization for this model of acute leukemia. However, it also suggests that aggressiveness of leu- Results are the mean of 15 mice/group pooled. Experiments have been done three times.
Figure 8
In vivo depletion of CD4 + and CD8 + T cells in vaccine experiments: after depletion and four subcutaneous injections of 10 6 irradiated IL12 transduced or control pCDNA3/Zeo DA1-3b cells, antileukemic immunity was challenged 1 week after the last injection of vaccine cells by i.p. injection of 2 × 10 4 wild-type DA1-3b cells in 10 to 20 C3H mice/group. kemic disease would limit the efficacy of gene therapy protocols in human patients. Recently reported results showed that IL12 gene therapy in a murine model of lymphoma was more effective when combined with chemotherapy. 27 These data suggest that immunotherapy of acute leukemia by ex vivo gene transfer would probably be more efficient in a situation of minimal residual disease. Careful evaluation of results obtained in various animal models seems a prerequisite before starting gene therapy clinical trials in acute leukemia.
